• Hausa Edition
  • Podcast
  • Conferences
  • LeVogue Magazine
  • Business News
  • Print Advert Rates
  • Online Advert Rates
  • Contact Us
Wednesday, September 9, 2026
Leadership Newspapers
No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
    • Football
  • Health
  • Entertainment
  • Education
  • Opinion
    • Editorial
    • Columns
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us
Hausa Edition
  • Home
  • News
  • Politics
  • Business
  • Sport
    • Football
  • Health
  • Entertainment
  • Education
  • Opinion
    • Editorial
    • Columns
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us
No Result
View All Result
Leadership Newspapers
No Result
View All Result

NAFDAC Refutes Report On Under-dosed Paracetamol Tablets In Nigeria

Says finding questionable

Patience Ivie Ihejirika by Patience Ivie Ihejirika
3 years ago
in Health
Mojisola
Share on WhatsAppShare on FacebookShare on XTelegram

The National Agency for Food and Drug Administration (NAFDAC) has described a recent publication of a research finding alleging that nearly all paracetamol tablets sold in Nigeria are under-dosed as misleading.

Director-general of NAFDAC, Prof. Mojisola Adeyeye, who made this known in a statement on Monday, also said that the science behind the finding was questionable.

She said, “NAFDAC is aware of a recent story presently being circulated on social media alleging that nearly all paracetamol tablets sold in Nigeria are under-dosed. We have received a copy of the publication of the research finding of the subject and we wish to state categorically that the report is misleading, and the science is questionable.

“As the quality culture of NAFDAC demands, as soon as the Agency became aware of the news, the Director General, had meetings with the respective directors and gave a directive that a survey of the market should be done to sample and test.”

The NAFDAC DG said she has met with the leadership of the Pharmaceutical Manufacturing Group of the Manufacturing Association of Nigeria (MAN) to inform them of the agency’s intent.

She explained that, “NAFDAC’s laboratories are ISO 17025-certified every year to ensure that the procedures used for testing are based on international standards and the equipment or instruments used are qualified similarly.

“We do yearly post-marketing survey of medicines to ensure that the quality and safety are maintained. Where there is a deviation from this, i.e., whenever we find any regulated product to be substandard or falsified, NAFDAC regularly issues public alerts or do recalls. In the last two years we have issued eighty-eight (88) public alerts and ordered thirty-two (32) recalls for medicines and foods.

RELATED NEWS

Sight Loss: 84% Of 24m Cases In Nigeria Preventable — OSN

Safe Water, Sanitation Key To Healthier Nigeria — Minister

Hypertension Crisis: Nigeria Funds Only 7% Of Required Investment

“We are using this medium to assure the public that NAFDAC is using international standards and scientific method to survey the paracetamol product where samples are collected from different parts of the country in the right amount and will be tested using well calibrated, and qualified state-of-the-art equipment or instruments.

“We want to reiterate that NAFDAC has five ISO-17025 Laboratories across the country, and a WHO Prequalified Laboratory at Yaba Lagos where medicines are tested for quality and safety. The laboratories test medicines using official monographs of British Pharmacopeia, United States Pharmacopoeia, and International Pharmacopoeia.”

Adeyeye assured Nigerians that they would be updated as soon as the agency was done with the laboratory testing.

“NAFDAC wishes to reassure the public that the agency is very vigilant in her responsibilities in safeguarding the health of the nation,” she added.

We’ve got the edge. Get real-time reports, breaking scoops, and exclusive angles delivered straight to your phone. Don’t settle for stale news. Join LEADERSHIP NEWS on WhatsApp for 24/7 updates →

Join Our WhatsApp Channel

Nigerians can invest ₦2.5million on premium domains and earn about ₦17-25Million. Earnings in USD. Rather than wonder, click here to find out how it works

Patience Ivie Ihejirika

Patience Ivie Ihejirika

Patience Ivie Ihejirika is an award-winning journalist with Leadership Newspaper, specialising in health reporting. She is known for in-depth coverage, compelling human-interest stories, and well-researched special reports that have distinguished her in the field.

OTHER NEWS UPDATES

Sight Loss: 84% Of 24m Cases In Nigeria Preventable — OSN
Health

Sight Loss: 84% Of 24m Cases In Nigeria Preventable — OSN

14 hours ago
Safe Water, Sanitation Key To Healthier Nigeria — Minister
Health

Safe Water, Sanitation Key To Healthier Nigeria — Minister

14 hours ago
Hypertension Crisis: Nigeria Funds Only 7% Of Required Investment
Health

Hypertension Crisis: Nigeria Funds Only 7% Of Required Investment

14 hours ago
Next Post
What Does Climate Justice Mean For Africa?

Climate Change: We Should Go After Industrialised Countries!

Advertisement

LATEST UPDATE

BREAKIN: Sanwo-Olu Approves Badejo Olawunmi As LASU Vice Chancellor  

50 seconds ago

Dangote Refinery IPO: Stanbic IBTC Commits To Market Access

52 minutes ago

Gabriel Jesus Marks Barcelona Champions League Debut With Goal In Feyenoord Rout

1 hour ago

Nigerian Stocks Sustain Decline, Loss N1.67trn

2 hours ago

FIFA U-20 Women’s World Cup: Nigerian Ambassador Lifts Falconets, Urges Focus On China Match

2 hours ago
Load More
Advertisement
Facebook Twitter Instagram Youtube Whatsapp

© 2026 LEADERSHIP Media Group - All Rights Reserved | Hausa | Online Casino.

No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
    • Football
  • Health
  • Entertainment
  • Education
  • Opinion
    • Editorial
    • Columns
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us

© 2026 LEADERSHIP Media Group - All Rights Reserved | Hausa | Online Casino.